Vagus Nerve Stimulation, HRV and Athletic Recovery: What the Evidence Shows

Introduction: Sorting the Signal From the Marketing

Vagus nerve stimulation (VNS) has found an enthusiastic audience among athletes and the wider wellness market, where ear-clip devices are promoted for faster recovery, better heart rate variability, and even improved performance. The appeal is understandable: recovery and parasympathetic "tone" are real concerns for anyone training hard. But the marketing has run well ahead of the evidence, and the honest picture is decidedly mixed.

This article separates what the controlled studies actually found from what the claims imply. The short version: there are some genuine positive signals for recovery markers, at least one intriguing finding for cardiorespiratory fitness in untrained volunteers, and a consistent failure to demonstrate improved athletic performance. Those are different things, and the difference is the whole story.

Why Athletes Are Interested: Vagal Tone, HRV and Recovery

The rationale rests on the autonomic nervous system. After hard exercise, the body shifts from sympathetic ("fight or flight") dominance back toward parasympathetic ("rest and digest") activity, and that recovery is partly driven by the vagus nerve. Athletes commonly track heart rate variability (HRV) as a window onto this balance, using higher HRV as a sign of good recovery and readiness to train. If a device could enhance vagal activity, the thinking goes, it might speed recovery and lift performance.

But there is a problem at the base of this chain of reasoning, and it deserves stating plainly. The assumption that taVNS reliably increases vagal tone is not well supported. A 2026 systematic review of neuromodulation and HRV found that transcutaneous VNS produced no consistent, significant effect on HRV across randomised trials (Souza et al., 2026). In other words, the most basic claim behind athletic VNS — that it dependably boosts vagal tone — is itself shaky. Everything built on top of it should be read with that in mind.

Recovery Markers Versus Performance: The Key Distinction

The clearest way to understand this evidence is to separate two questions: does VNS help you recover, and does it make you perform better? The studies suggest these have different answers.

Hatik et al. (2023), in Brain and Behavior, studied 90 healthy young adults using taVNS around cycling exercise. Bilateral stimulation produced positive effects on recovery markers — reductions in post-exercise pain, fatigue, and blood lactate compared with control conditions. However, there was no statistically significant improvement in actual cycling performance (the distance covered). Recovery markers improved; the performance outcome did not.

Çalı et al. (2024), in Expert Review of Medical Devices, ran an open-label randomised trial of a single taVNS session in 60 elite athletes. Although a few isolated measures shifted, the overall conclusion was negative: a single session of stimulation did not produce a statistically significant improvement in athletic performance compared with sham. The authors concluded that single-use stimulation "seems not effective in improving athletic performance".

The pattern across both is consistent: stimulation may nudge some recovery-related markers, but it has not been shown to make athletes measurably faster, stronger, or more capable. For anyone buying a device to improve performance, that is the finding that matters.

A Signal for Cardiorespiratory Fitness?

One study complicates the picture in an interesting way. Ackland et al. (2025), in the European Heart Journal, conducted a double-blind, sham-controlled crossover trial in 28 healthy volunteers. After seven days of non-invasive VNS, peak oxygen uptake (VO2peak) — a core measure of cardiorespiratory fitness — increased by 1.04 mL/kg/min (P = 0.005) compared with no change under sham, alongside small increases in peak work rate and a reduced inflammatory response.

This is a real, positive, properly controlled result, and it should be reported as such. But it carries heavy caveats: the participants were healthy volunteers, not trained athletes; the sample was small; it was a single centre; and the absolute effect (a roughly 3–4% change in VO2peak) is modest. Whether such an effect would appear, or matter, in already-fit athletes is unknown. It is a reason for further study, not a basis for performance claims.

The HRV Question

Because so much athletic VNS marketing is built around HRV, it is worth returning to it directly. HRV is a useful, well-validated marker of autonomic balance, and it genuinely reflects vagal activity. The issue is not HRV itself but the claim that these devices reliably raise it. As noted above, the best current synthesis of the randomised evidence found no consistent effect of transcutaneous VNS on HRV (Souza et al., 2026).

That does not mean the devices never influence autonomic activity — individual studies have shown effects in specific settings — but it does mean a blanket promise to "improve your HRV" is not supported by the weight of the evidence. Readers tracking HRV should be sceptical of any product that treats that outcome as guaranteed.

Practical Reality and Hype

Putting it together, the athletic case for VNS is a clear illustration of how a plausible mechanism and a few positive markers can be inflated into broad performance claims. The recovery signals are real but inconsistent and mostly limited to subjective or biochemical markers; the performance evidence is essentially negative; the headline HRV claim is not reliably supported; and the one fitness signal comes from untrained volunteers. None of that adds up to the transformative recovery-and-performance tool that marketing often describes.

Why "Better Markers" Is Not "Better Performance"

The recurring theme across this evidence — improved recovery markers alongside unchanged performance — is worth dwelling on, because it is exactly where athletic claims tend to overreach. A reduction in post-exercise lactate, pain, or subjective fatigue is a measurable physiological change, and it is easy to present such a finding as proof that a device "works". But the outcomes athletes actually care about — how far, how fast, how strong — are what the controlled trials measured directly, and those did not reliably move.

There are good reasons the two can diverge. Subjective fatigue and some biochemical markers are sensitive to expectation and to the simple act of doing something structured after exercise, whereas performance tests are harder to influence by belief alone. A marker can shift without the underlying capacity changing. This is why the most useful question to ask of any recovery technology is not "did some marker improve?" but "did it improve an outcome that matters, against a credible control?" — and on that test, the athletic VNS evidence has so far come up short.

For anyone making training decisions, the practical implication is to weight the hard performance outcomes far more heavily than the recovery-marker and HRV claims that dominate the marketing.

What Would Actually Count as Evidence

It is worth spelling out what convincing evidence for athletic vagus nerve stimulation would look like, because the gap between that standard and the current studies is the real story. A persuasive trial would be double-blind and sham-controlled, so that neither athletes nor assessors knew who received real stimulation — essential when the outcomes are partly subjective and expectation runs high in performance settings. It would measure outcomes that matter directly: time-trial performance, power output, or competition results, rather than recovery markers used as stand-ins. It would study trained athletes rather than untrained volunteers, since the two respond very differently to any intervention. And it would be adequately powered, use a realistic stimulation protocol over a meaningful training period, and ideally be replicated by an independent group.

Measured against that standard, the existing evidence falls short on most counts: small samples, mostly single sessions, frequent reliance on surrogate recovery markers, and — in the one positive fitness result — untrained participants rather than athletes. None of this means a real effect is impossible; it means the studies done so far are not the studies that could establish one.

For an athlete deciding whether to spend money and attention on a device, that is the practical bottom line. The claims are running ahead of a body of evidence that has not yet been built to the standard those claims would require.

Safety

Non-invasive taVNS is generally well tolerated, with side effects usually limited to mild local tingling — see our review of the safety profile of VNS. For athletes, the practical risk is therefore less about harm and more about spending money and attention on an intervention whose performance benefits are unproven.

The Bottom Line

For athletic recovery and performance, the evidence does not match the marketing:

- The HRV/vagal-tone rationale is appealing, but taVNS does not reliably raise HRV (Souza et al., 2026).
- Some recovery markers (pain, fatigue, lactate) improved in places, but performance outcomes did not (Hatik et al., 2023).
- A randomised trial in elite athletes found no significant performance benefit from a single session (Çalı et al., 2024).
- One controlled trial found a modest cardiorespiratory-fitness gain — in untrained healthy volunteers, not athletes (Ackland et al., 2025).

The honest summary: vagus nerve stimulation is not an established way to recover faster or perform better. There are scattered positive signals worth further research, but anyone buying a device on the promise of improved performance is getting ahead of the evidence. For the underlying science of vagal tone and recovery, see our article on VNS and HRV, and browse the studies in our Evidence Database.

---

References

Ackland, G.L. et al. (2025). Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial. European Heart Journal, 46(17), 1634–1644.

Çalı, A. et al. (2024). Effects of a single session of noninvasive auricular vagus nerve stimulation on sports performance in elite athletes: an open-label randomized controlled trial. Expert Review of Medical Devices, 21(3), 231–237.

Hatik, S.H. et al. (2023). The effect of transcutaneous auricular vagus nerve stimulation on cycling ergometry and recovery in healthy young individuals. Brain and Behavior, 13(12), e3332.

Souza, R. et al. (2026). Neuromodulation of heart rate variability: a systematic review. Autonomic Neuroscience, 263, 103379.